Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study
Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centre for Research and Development, Gävleborg. Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden..
Karolinska Inst, Dept Lab Med, SE-14186 Stockholm, Sweden..
Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden..
Show others and affiliations
2016 (English)In: BMJ-BRITISH MEDICAL JOURNAL, ISSN 1756-1833, Vol. 352, i276Article in journal (Refereed) Published
Resource type
Text
Abstract [en]

OBJECTIVES To investigate the risks of invasive cervical cancer after detection of atypical glandular cells (AGC) during cervical screening. DESIGN Nationwide population based cohort study. SETTING Cancer and population registries in Sweden. PARTICIPANTS 3 054 328 women living in Sweden at any time between 1 January 1980 and 1 July 2011 who had any record of cervical cytological testing at ages 23-59. Of these, 2 899 968 women had normal cytology results at the first screening record. The first recorded abnormal result was atypical glandular cells (AGC) in 14 625, high grade squamous intraepithelial lesion (HSIL) in 65 633, and low grade squamous intraepithelial lesions (LSIL) in 244 168. MAIN OUTCOME MEASURES Cumulative incidence of invasive cervical cancer over 15.5 years; proportion of invasive cervical cancer within six months of abnormality (prevalence); crude incidence rates for invasive cervical cancer over 0.5-15.5 years of follow-up; incidence rate ratios compared with women with normal cytology, estimated with Poisson regression adjusted for age and stratified by histopathology of cancer; distribution of clinical assessment within six months after the abnormality. RESULTS The prevalence of cervical cancer was 1.4% for women with AGC, which was lower than for women with HSIL (2.5%) but higher than for women with LSIL (0.2%); adenocarcinoma accounted for 73.2% of the prevalent cases associated with AGC. The incidence rate of invasive cervical cancer after AGC was significantly higher than for women with normal results on cytology for up to 15.5 years and higher than HSIL and LSIL for up to 6.5 years. The incidence rate of adenocarcinoma was 61 times higher than for women with normal results on cytology in the first screening round after AGC, and remained nine times higher for up to 15.5 years. Incidence and prevalence of invasive cervical cancer was highest when AGC was found at ages 30-39. Only 54% of women with AGC underwent histology assessment within six months, much less than after HSIL (86%). Among women with histology assessment within six months, the incidence rate of cervical cancer after AGC was significantly higher than that after HSIL for up to 6.5 years. CONCLUSIONS AGC found at cervical screening is associated with a high and persistent risk of cervical cancer for up to 15 years, particularly for cervical adenocarcinoma and women with AGC at age 30-39. Compared with the reduction in risk of cancer seen after HSIL management, management of AGC seems to have been suboptimal in preventing cervical cancer. Research to optimise management is needed, and a more aggressive assessment strategy is warranted.

Place, publisher, year, edition, pages
2016. Vol. 352, i276
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-280243DOI: 10.1136/bmj.i276ISI: 000370383900001PubMedID: 26869597OAI: oai:DiVA.org:uu-280243DiVA: diva2:910547
Funder
Swedish Foundation for Strategic Research
Available from: 2016-03-09 Created: 2016-03-09 Last updated: 2016-03-09Bibliographically approved

Open Access in DiVA

fulltext(601 kB)52 downloads
File information
File name FULLTEXT01.pdfFile size 601 kBChecksum SHA-512
c7a965d3c115da8383a2fa7d63f918e9a5ca2e9ff152c25de6013035f99d0371d16d7028d048e74da4b9070addd7e2494925c130027eec75dadadc785479d28c
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed
By organisation
Centre for Research and Development, Gävleborg
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 52 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 238 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf